Targeted degradation of α-Synuclein using an evolved botulinum toxin protease

Area of Science:

• Biochemistry
• Molecular Biology
• Neuroscience

Background:

• Targeted protein degradation is crucial for treating diseases caused by protein dysfunction.
• Engineering sequence-specific proteases for precise protein targeting is challenging due to complex enzyme-substrate interactions.
• Alpha-Synuclein (α-Synuclein) is a key protein implicated in the pathogenesis of Parkinson's disease.

Purpose of the Study:

• To develop a novel strategy for evolving proteases with tailored specificity.
• To engineer a protease capable of programmed degradation of α-Synuclein.
• To demonstrate the efficacy and safety of the engineered protease in human cells.

Main Methods:

• Structure-guided evolution of a botulinum neurotoxin protease.
• Stepwise modification of protease specificity from its native substrate (SNAP25) to α-Synuclein.
• In vitro and in cell-based assays to assess degradation efficiency and cellular effects.

Main Results:

• Successfully evolved a protease to specifically target and degrade α-Synuclein.
• Demonstrated near-complete degradation of overexpressed human α-Synuclein in human cells.
• Confirmed no significant impact on cell proliferation, indicating high selectivity and safety.

Conclusions:

• A stepwise, structure-guided evolution approach can yield highly selective proteases for targeted protein degradation.
• Engineered proteases targeting α-Synuclein offer a potential therapeutic strategy for Parkinson's disease.
• This methodology may be broadly applicable for developing proteases against other disease-associated proteins.